IPP Bureau
USFDA approves Imjudo in combination with Imfinzi for liver cancer
By IPP Bureau - October 26, 2022
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
Novartis maintains growth momentum; Confirms FY’22 Group guidance
By IPP Bureau - October 26, 2022
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
AstraZeneca updates on the MESSINA Phase III trial for Fasenra in eosinophilic esophagitis
By IPP Bureau - October 26, 2022
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
Zydus receives final approval from USFDA for Micafungin for Injection
By IPP Bureau - October 26, 2022
Micafungin for Injection had annual sales of US $99 million in the United States according to IQVIA data
Biocon Biologics insulins facility in Malaysia receives EU GMP Certification
By IPP Bureau - October 26, 2022
The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.
Lupin launches Paliperidone Extended-Release Tablets in US
By IPP Bureau - October 24, 2022
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 112 million in the U.S. (IQVIA MAT August 2022).
Aster DM Healthcare to acquire Sr Sainatha Multispeciality Hospitals
By IPP Bureau - October 24, 2022
Jubilant Pharmova Q2FY23 consolidated PAT drops to Rs. 5.49 Cr
By IPP Bureau - October 23, 2022
The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.
Glenmark Life Sciences Q2FY23 PAT slips to Rs. 106.87 Cr
By IPP Bureau - October 23, 2022
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
Govt celebrates 7th Ayurveda Day 2022
By IPP Bureau - October 23, 2022
A MoU was signed between Ministry of Ayush and Ministry of Tribal Affairs to collaborate in Ayush sector
Merck’s PREVYMIS effective for prevention of cytomegalovirus disease in adults post kidney transplantation
By IPP Bureau - October 23, 2022
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
IHL Launches Heart Health Calculator
By IPP Bureau - October 23, 2022
Tech-driven calculator, which serves as a preventive tool that helps in heart risk assessment using several factors
Aragen to operationalize Hyderabad formulation manufacturing facility by Jan 2023
By IPP Bureau - October 21, 2022
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
Glenmark launches Zita D for adults with Type 2 diabetes having comorbidities
By IPP Bureau - October 21, 2022
A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities
Aster Hospital opens 100-bed multi-specialty facility in Sharjah
By IPP Bureau - October 21, 2022
The newest facility has all the core specialties like Obstetrics and Gynaecology, Orthopaedics, Neurology, Cardiology, Paediatrics, General Surgery, and Urology
